Find a Trial

Trial Summary

Protocol No.BTCRC-LUN17-127
Principal InvestigatorHanna, Nasser
PhasePhase I/II
Age GroupAdult
TitleA Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer
DescriptionAn open-label Phase I/II study, with a dose escalation part (Phase I) and a 2-arm randomized part (Phase II), in patients with recurrent SCLC.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • 18 Years and older
  • Histological or cytological confirmed extensive-stage SCLC
  • Patients who progressed after at least 1 platinum-based chemotherapy regimen
For a full list of participation criteria, please visit
Applicable Disease SitesLung
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632